This site uses cookies to bring you the best experience. Find out more
Skip to main content

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  


Intuitive Announces New UK Headquarters in Oxford

OXFORD, England–Intuitive (Nasdaq: ISRG), a global leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the opening of its United Kingdom and Republic of Ireland headquarters and training suite at Oxford Science Park’s Schrödinger Building. “Oxford is internationally renowned for medical and scientific innovation and we are proud to expand our collaboration with this community that we think... Read more

Blue Earth Diagnostics to be Acquired by Global Leader Bracco Imaging

27th June 2019 ‒ Blue Earth Diagnostics to become a subsidiary of Bracco Imaging; retains name and management team ‒ ‒ Acquisition driven by lead product Axumin® (fluciclovine F 18), a novel molecular imaging agent for use with PET imaging to detect recurrent prostate cancer, and a robust pipeline ‒ ‒ Combined business will leverage Bracco’s diagnostic modalities, global competencies, portfolio and financial resources ‒ BURLINGTON,... Read more

Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer

Oxford, UK – April 16, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that Axumin (fluciclovine (18F)) has recently been added to the European Association of Urology (EAU) 2019 Clinical Practice Guidelines in Oncology for Prostate Cancer (PCa). The EAU PCa Guidelines assist clinicians in making informed decisions, taking into consideration the scientific data available and individual... Read more

Blue Earth Diagnostics celebrates five year anniversary

Oxford, UK – March 6, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, recently celebrated the company’s five year anniversary. During this time, Blue Earth Diagnostics has delivered five years of innovation and continued growth with a proven track record and depth of expertise in the rapid development and global commercialization of radiopharmaceuticals for cancer management. Blue Earth Diagnostics employs... Read more

Vaccitech Awarded BARDA contract valued at $8.5M to conduct Phase II trial for Influenza Vaccine

Oxford, UK – 4 March 2019 Vaccitech announced today that it has been awarded a contract valued at $8.5 million from the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, for the advanced clinical development of its recombinant Modified Vaccinia Ankara (MVA) vaccine candidate for prevention of seasonal... Read more

The Daubeny Project

Imaginative design, inspiring spaces.